Form Type:  8-K
Filing Date:  5/20/2014 
CIK:  0001010086 
Address:  660 MADISON AVENUE
SUITE 1700
City, State, Zip:  NEW YORK, New York 10065 
Telephone:  212-672-9100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.02 (0.66%)  
Trade Time: 
11:02 AM EST  
Market Cap: 
Trade SIGA now with 

© 2016  
Description of Business
We are a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is TPOXX(TM), also known as Tecovirimat or ST-246®, an orally administered antiviral drug that targets orthopoxvirus infections. While TPOXX(TM) is not yet approved as safe or effective by the FDA, it is a novel small-molecule drug that is being developed with support from BARDA and delivered to the Strategic Stockpile under Project BioShield. BARDA Contract - TPOXX(TM), also known as Tecovirimat or ST-246® On May 13, 2011, the Company signed the BARDA Contract pursuant to which we agreed to deliver two million courses of TPOXX(TM) to the Strategic Stockpile. The BARDA Contract is worth approximately $470 million, including $409.8 million for manufacture and delivery of 1.7 million courses of TPOXX(TM) and $60 million of potential reimbursements related to development and supportive activities (the "Base Contract").
Register and access this filing in:     
  FORM 8-K
      Item 5.07. Submission of Matters to a Vote of Security Holders.